1. Home
  2. MREO vs FSBW Comparison

MREO vs FSBW Comparison

Compare MREO & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • FSBW
  • Stock Information
  • Founded
  • MREO 2015
  • FSBW 1936
  • Country
  • MREO United Kingdom
  • FSBW United States
  • Employees
  • MREO N/A
  • FSBW N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • FSBW Banks
  • Sector
  • MREO Health Care
  • FSBW Finance
  • Exchange
  • MREO Nasdaq
  • FSBW Nasdaq
  • Market Cap
  • MREO 311.8M
  • FSBW 306.0M
  • IPO Year
  • MREO N/A
  • FSBW 2012
  • Fundamental
  • Price
  • MREO $1.84
  • FSBW $40.19
  • Analyst Decision
  • MREO Strong Buy
  • FSBW Hold
  • Analyst Count
  • MREO 5
  • FSBW 1
  • Target Price
  • MREO $7.40
  • FSBW $44.00
  • AVG Volume (30 Days)
  • MREO 1.6M
  • FSBW 13.7K
  • Earning Date
  • MREO 11-10-2025
  • FSBW 10-21-2025
  • Dividend Yield
  • MREO N/A
  • FSBW 2.76%
  • EPS Growth
  • MREO N/A
  • FSBW N/A
  • EPS
  • MREO N/A
  • FSBW 4.09
  • Revenue
  • MREO $500,000.00
  • FSBW $140,954,000.00
  • Revenue This Year
  • MREO N/A
  • FSBW $10.46
  • Revenue Next Year
  • MREO $72.16
  • FSBW $4.42
  • P/E Ratio
  • MREO N/A
  • FSBW $9.92
  • Revenue Growth
  • MREO N/A
  • FSBW 1.07
  • 52 Week Low
  • MREO $1.47
  • FSBW $34.61
  • 52 Week High
  • MREO $4.29
  • FSBW $48.60
  • Technical
  • Relative Strength Index (RSI)
  • MREO 45.03
  • FSBW 57.91
  • Support Level
  • MREO $1.65
  • FSBW $37.34
  • Resistance Level
  • MREO $1.93
  • FSBW $41.21
  • Average True Range (ATR)
  • MREO 0.12
  • FSBW 1.04
  • MACD
  • MREO -0.02
  • FSBW 0.31
  • Stochastic Oscillator
  • MREO 36.00
  • FSBW 83.61

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

Share on Social Networks: